Small molecule engagement of the GLP-1 receptor using affinity selection mass spectrometry (ASMS) proved to be a productive starting point for drug discovery, with a 50,000 compound diversity screen identifying three structurally distinct hit series that could be expanded and characterized in depth. Hit expansion across 52 analogs established clear structure-activity relationships within 3 scaffolds.
